浏览全部资源
扫码关注微信
1.湖北民族大学 医学部,湖北 恩施 445000
2.湖北民族大学 武陵山中药材检验检测中心,湖北 恩施 445000
李鸿,在读硕士,从事民族医药的挖掘、整理、保护、开发与利用,E-mail:hbmzlh@qq.com
涂星,博士,讲师,从事民族医药的挖掘、整理、保护、开发与利用,E-mail:2015030@hbmzu.edu.cn
收稿日期:2022-08-23,
网络出版日期:2022-11-11,
纸质出版日期:2023-02-05
移动端阅览
李鸿,于官正,胡雪黎等.基于网络药理学与实验验证探讨四君子汤与痛泻要方“同病异治”溃疡性结肠炎的作用机制[J].中国实验方剂学杂志,2023,29(03):52-60.
LI Hong,YU Guanzheng,HU Xueli,et al.Mechanisms of Si Junzitang and Tongxie Yaofang Against Ulcerative Colitis Following "Same Disease with Different Treatments" Based on Network Pharmacology and Experimental Verification[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(03):52-60.
李鸿,于官正,胡雪黎等.基于网络药理学与实验验证探讨四君子汤与痛泻要方“同病异治”溃疡性结肠炎的作用机制[J].中国实验方剂学杂志,2023,29(03):52-60. DOI: 10.13422/j.cnki.syfjx.20221711.
LI Hong,YU Guanzheng,HU Xueli,et al.Mechanisms of Si Junzitang and Tongxie Yaofang Against Ulcerative Colitis Following "Same Disease with Different Treatments" Based on Network Pharmacology and Experimental Verification[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(03):52-60. DOI: 10.13422/j.cnki.syfjx.20221711.
目的
2
基于网络药理学挖掘并预测四君子汤与痛泻要方同病异治抗溃疡性结肠炎(UC)的作用靶点及相关信号通路,并研究其作用机制。
方法
2
GEO数据库筛选UC患者差异表达基因;中药系统药理学数据库与分析平台(TCMSP)获得复方化学成分及对应靶点;构建中药复方调控网络;绘制蛋白质-蛋白质相互作用(PPI)网络,预测核心基因;进行富集分析。用葡聚糖硫酸钠(DSS)诱导UC小鼠模型,小鼠随机分为正常组、UC组、四君子汤组、痛泻要方组与美沙拉嗪组,连续给药14 d,进行疾病活动指数(DAI)评分;测算血液流变学特征值;检测血清白细胞介素-6(IL-6)、组织因子(TF)、缺氧诱导因子-1
α
(HIF-1
α
)含量变化;测算核转录因子(NF)-
κ
B抑制因子蛋白激酶
α
(IKK
α
)、NF-
κ
B、HIF-1
α
、血管内皮细胞生长因子(VEGF)mRNA的相对表达量。
结果
2
通过网络药理学分析获得两复方与UC交集基因共44个,包含17个共性基因。HIF-1通路、缺氧反应等为两复方治疗UC潜在共性靶点。结果显示两复方能够显著降低DAI评分;显著提高血流灌注量、血细胞移动速度,降低移动红细胞浓度;显著降低IL-6、TF、HIF-1
α
的水平;显著降低IKK
α
、NF-
κ
B、HIF-1
α
、VEGF mRNA的表达量。
结论
2
HIF-1通路及相关靶标可能为两复方发挥同病异治作用的共性靶点,四君子汤长于行气改善肠组织缺氧状态,痛泻要方长于活血促进肠黏膜微循环。
Objective
2
To predict the targets and signaling pathways of Si Junzitang and Tongxie Yaofang in treating ulcerative colitis (UC) following the concept of "same disease with different treatments" based on the network pharmacology and explore the underlying mechanisms.
Method
2
The differentially expressed genes (DEGs) of UC were extracted from GeoChip. The active components and corresponding potential targets of Si Junzitang and Tongxie Yaofang were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). The regulatory networks of Si Junzitang and Tongxie Yaofang were constructed and the protein-protein interaction (PPI) network was plotted. The core genes were predicted, followed by enrichment analysis. The UC model was induced in mice by dextran sodium sulfate (DSS) solution. Mice were randomly divided into a normal group, a UC group, a Si Junzitang group, a Tongxie Yaofang group, and a mesalazine group. Drugs were administered continuously for 14 days. The disease activity index (DAI) was scored for mice in each group. The characteristic values of hemorheology were measured. The serum levels of interleukin-6 (IL-6), tissue factor (TF), and hypoxia-inducible factor-1
α
(HIF-1
α
) in mice were detected. The relative mRNA expression levels of inhibitory kappa B kinase
α
(IKK
α
), nuclear factor kappa B (NF-
κ
B), HIF-1
α
, and vascular endothelial growth factor (VEGF) were measured.
Result
2
A total of 44 genes were obtained by network pharmacological analysis, including 17 common genes. HIF-1 pathway and hypoxia response were potential common targets of Si Junzitang and Tongxie Yaofang in the treatment of UC. The results showed that Si Junzitang and Tongxie Yaofang could significantly reduce DAI score, increase blood perfusion volume and blood cell movement speed, decrease the concentration of mobile red blood cells, reduce the levels of IL-6, TF, and HIF-1
α
, down-regulate the mRNA expression of IKK
α
, NF-
κ
B, HIF-1
α
, and VEGF.
Conclusion
2
The HIF-1 pathway and related targets may be the common targets of Si Junzitang and Tongxie Yaofang to exert different therapeutic effects on the same disease. Si Junzitang is potent in promoting Qi circulation to improve intestinal tissue hypoxia, and Tongxie Yaofang is effective in promoting blood circulation to facilitate intestinal mucosal microcirculation.
崔畅婉 , 孙峥嵘 . 溃疡性结肠炎发病机制研究进展 [J]. 现代免疫学 , 2019 , 39 ( 1 ): 77 - 81 .
AKIHO H , YOKOYAMA A , ABE S , et al . Promising biological therapies for ulcerative colitis:A review of the literature [J]. World J Gastrointest Pathophysiol , 2015 , 6 ( 4 ): 219 - 227 .
李红琳 , 陈江 . 溃疡性结肠炎及其不同中医证型肠道菌群研究概况 [J]. 中国中医药信息杂志 , 2021 , 28 ( 5 ): 137 - 140 .
孙豪娴 , 孙贵香 , 朱莹 . 黄芩汤治疗溃疡性结肠炎的研究现状 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 23 ): 219 - 227 .
沈洪 , 唐志鹏 , 唐旭东 , 等 . 消化系统常见病溃疡性结肠炎中医诊疗指南(基层医生版) [J]. 中华中医药杂志 , 2019 , 34 ( 9 ): 4155 - 4160 .
黄晓燕 , 张涛 , 王囡囡 , 等 . 端粒缩短介导肠上皮细胞凋亡参与溃疡性结肠炎以及四君子汤干预研究 [J]. 时珍国医国药 , 2014 , 25 ( 9 ): 2303 - 2305 .
黄晓燕 , 马媛萍 , 李桂贤 , 等 . 四君子汤含药血清调控hTERT,TRF1,Tankyrase表达及对UCAC的影响 [J]. 中国实验方剂学杂志 , 2018 , 24 ( 8 ): 128 - 133 .
张旭飞 , 罗运凤 , 高洁 , 等 . 痛泻要方对肝郁脾虚型溃疡性结肠炎大鼠脂质代谢及自噬的影响 [J]. 中成药 , 2022 , 44 ( 3 ): 739 - 746 .
沈洪 , 唐志鹏 , 唐旭东 , 等 . 消化系统常见病溃疡性结肠炎中医诊疗指南(基层医生版) [J]. 中华中医药杂志 , 2019 , 34 ( 9 ): 4155 - 4160 .
刘志华 , 孙晓波 . 网络药理学:中医药现代化的新机遇 [J]. 药学学报 , 2012 , 47 ( 6 ): 696 - 703 .
WANG J , LI X J . Drug targets discovery based on dynamic signal transduction networks [J]. Acta pharmaceutica Sinica , 2010 , 45 ( 1 ): 1 - 8 .
BARRETT T , WILHITE S E , LEDOUX P , et al . NCBI GEO:Archive for functional genomics data sets-update [J]. Nucleic Acids Res , 2013 , 41 ( Database issue ): D991 - D995 .
LIPINSKI C A , LOMBARDO F , DOMINY B W , et al . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J]. Adv Drug Deliv Rev , 2001 , 46 ( 1/3 ): 3 - 26 .
VEBER D F , JOHNSON S R , CHENG H Y , et al . Molecular properties that influence the oral bioavailability of drug candidates [J]. J Med Chem , 2002 , 45 ( 12 ): 2615 - 2623 .
RU J , LI P , WANG J , et al . TCMSP:A database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform , 2014 , 6 : 13 .
XU X , ZHANG W , HUANG C , et al . A novel chemometric method for the prediction of human oral bioavailability [J]. Int J Mol Sci , 2012 , 13 ( 6 ): 6964 - 6982 .
SHANNON P , MARKIEL A , OZIER O , et al . Cytoscape:A software environment for integrated models of biomolecular interaction networks [J]. Genome Res , 2003 , 13 ( 11 ): 2498 - 2504 .
葛俊李 , 李芳 , 王春霞 , 等 . 溃疡性结肠炎动物模型的研究进展 [J]. 中华中医药学刊 , 2022 , 40 ( 11 ): 165 - 170,288 .
彭琳秀 , 单进军 , 钱文娟 , 等 . 基于UPLC-Q-Exactive Orbitrap MS的类风湿性关节炎大鼠脂质代谢紊乱及祖师麻片的干预作用研究 [J]. 中草药 , 2018 , 49 ( 18 ): 4356 - 4365 .
NG S C , SHI H Y , HAMIDI N , et al . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies [J]. Lancet , 2017 , 390 ( 10114 ): 2769 - 2778 .
WEI S C , SOLLANO J , HUI Y T , et al . Epidemiology,burden of disease,and unmet needs in the treatment of ulcerative colitis in Asia [J]. Expert Rev Gastroenterol Hepatol , 2021 , 15 ( 3 ): 275 - 289 .
曹云 , 郭志玲 , 何莹 , 等 . 田德禄论治溃疡性结肠炎经验 [J]. 北京中医药 , 2020 , 39 ( 1 ): 23 - 26 .
朱庆平 , 沈洪 , 朱磊 . 中医对溃疡性结肠炎患者瘀血病机的认识 [J]. 浙江中医药大学学报 , 2013 , 37 ( 4 ): 480 - 482 .
纪云飞 , 王瑞君 , 李晓波 . 复方四君子汤的化学成分和药理作用研究进展 [J]. 中草药 , 2016 , 47 ( 5 ): 837 - 843 .
章宸 , 刘斌 , 郑虎占 , 等 . 痛泻要方药理作用和临床应用研究概况 [J]. 中国实验方剂学杂志 , 2010 , 16 ( 7 ): 223 - 226 .
TIAN Y , ZHENG Y , TENG G , et al . Imbalanced mucosal microcirculation in the remission stage of ulcerative colitis using probe-based confocal laser endomicroscopy [J]. BMC Gastroenterol , 2019 , 19 ( 1 ): 114 .
熊艳玲 , 钟薏文 , 陈雅茜 , 等 . 基于抗炎和氧化应激角度研究参苓白术颗粒对脾虚湿困溃疡性结肠炎大鼠的作用机制 [J]. 中药新药与临床药理 , 2021 , 32 ( 2 ): 149 - 157 .
吴东升 , 曹晖 , 张彧 , 等 . 芍药汤通过抑制HIF-1 α 调节Th17/Treg平衡治疗溃疡性结肠炎 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 16 ): 9 - 15 .
HE H L , ZHANG J B , LI Q . Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis [J]. World J Gastroenterol , 2014 , 20 ( 23 ): 7461 .
DEBAN L , CORREALE C , VETRANO S , et al . Multiple pathogenic roles of microvasculature in inflammatory bowel disease:A Jack of all trades [J]. Am J Pathol , 2008 , 172 ( 6 ): 1457 - 1466 .
翟勇聪 , 夏顺利 , 王雪 , 等 . 附子-干姜对慢性溃疡性结肠炎小鼠肠黏膜微循环障碍的改善作用 [J]. 中草药 , 2021 , 52 ( 7 ): 1987 - 1993 .
刘笃佳 , 王媛媛 , 马旭 . 溃疡性结肠炎的流行病学研究进展 [J]. 中国烧伤创疡杂志 , 2017 , 29 ( 3 ): 214 - 217 .
TAWARA K , SCOTT H , EMATHINGER J , et al . HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival:Synergistic induction of IL-6 secretion by OSM and IL-1 β [J]. Oncotarget , 2019 , 10 ( 21 ): 2068 - 2085 .
BALDWIN A S J R . Series introduction:The transcription factor NF-kappaB and human disease [J]. J Clin Invest , 2001 , 107 ( 1 ): 3 - 6 .
KAUSHIK D K , THOUNAOJAM M C , MITRA A , et al . Vespa tropica venom suppresses lipopolysaccharide-mediated secretion of pro-inflammatory cyto-chemokines by abrogating nuclear factor- κ B activation in microglia [J]. Inflamm Res , 2014 , 63 ( 8 ): 657 - 665 .
陈吉 , 高美丽 , 白晓茹 , 等 . 核因子- κ B和细胞因子在溃疡性结肠炎中的表达及其意义 [J]. 世界华人消化杂志 , 2009 , 17 ( 2 ): 209 - 212 .
FRYSZ-NAGLAK D , FRYC B , KLIMACKA-NAWROT E , et al . Expression,localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis [J]. Int Immunopharmacol , 2011 , 11 ( 2 ): 220 - 225 .
曾鹏 , 周航 . 网络药理学“异病-异方”关键成分筛选同质化现象思考 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 18 ): 177 - 191 .
董培良 , 李慧 , 韩华 . 中药网络药理学的应用与思考 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 17 ): 204 - 211 .
宋玮 , 郑伟 , 张洁 , 等 . 中药皂苷类成分的体内代谢研究进展 [J]. 药学学报 , 2018 , 53 ( 10 ): 1609 - 1619 .
陈健 , 陈启龙 . 网络药理学在中医药研究中的现状及思考 [J]. 上海中医药大学学报 , 2021 , 35 ( 5 ): 1 - 6,13 .
0
浏览量
37
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构